AU2022201543A1 - Brain-invigorating composition and preparation method thereof - Google Patents
Brain-invigorating composition and preparation method thereof Download PDFInfo
- Publication number
- AU2022201543A1 AU2022201543A1 AU2022201543A AU2022201543A AU2022201543A1 AU 2022201543 A1 AU2022201543 A1 AU 2022201543A1 AU 2022201543 A AU2022201543 A AU 2022201543A AU 2022201543 A AU2022201543 A AU 2022201543A AU 2022201543 A1 AU2022201543 A1 AU 2022201543A1
- Authority
- AU
- Australia
- Prior art keywords
- parts
- brain
- test
- invigorating
- invigorating composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present disclosure discloses a brain-invigorating composition and a
preparation method thereof. The brain-invigorating composition is composed of the
following raw materials in parts by weight: a DHA-containing algal oil 40-42 parts, an
extract of Bacopa monnieri 13-15 parts, tyrosine 1-2 parts, L-lysine monohydrochloride
1-2 parts, glutamine 1-2 parts, a choline bitartrate powder 1.5-2.5 parts, a flaxseed oil
0.5-1 parts, phospholipids 1-1.5 parts, glyceryl monostearate/distearate 1-1.5 parts, and
D-alpha-tocopherol 0.2-0.4 parts. Demonstrated by the relevant tests, the
brain-invigorating composition, with scientific and reasonable proportions, is capable of
significantly improving attention, concentration, memory, learning ability, and language
comprehension. There is no obvious change in the important blood indicators of the
human body after taking the brain-invigorating composition. Even if there is a change, it
is within a reasonable range. Thus, taking the brain-invigorating composition would not
cause a negative impact on the human body.
Description
[0001] The present disclosure relates to the field of health care, and specifically relates
to a brain-invigorating composition and a preparation method thereof.
[0002] As the society develops, the public pays more and more attention to brain health.
Generally, the brain would inevitably age to a certain degree as we grow older. However,
we could slow down the aging speed of brain through various methods such as diet and
health care. In fact, the brain aging also occurs in young people, mainly manifested in
inattention, memory decline, and poor language comprehension.
[0003] However, since the existing products lack the technical means for solving the
above problems, the present disclosure is proposed.
[0004] To solve the problems existing in the prior art, the present disclosure provides a
brain-invigorating composition and a preparation method thereof. Demonstrated by the
relevant tests, the brain-invigorating composition, with scientific and reasonable
proportions, is capable of significantly improving attention, concentration, memory,
learning ability, and language comprehension. There is no obvious change in the
important blood indicators of the human body after taking the brain-invigorating
composition. Even if there is a change, it is within a reasonable range. Thus, taking the
brain-invigorating composition would not cause a negative impact on the human body.
[0005] The solution of the present disclosure is providing the brain-invigorating
composition which comprises the following raw materials: a DHA-containing algal oil,
an extract of Bacopa monnieri, tyrosine, L-lysine monohydrochloride, glutamine, a
choline bitartrate powder, flaxseed oil, phospholipids, glyceryl monostearate/distearate,
and D-alpha-tocopherol.
[0006] A purity of the DHA-containing algal oil is 40%, and the extract of Bacopa monnieri is selected from commercially available products with an extraction ratio of : 1.
[0007] Preferably, the brain-invigorating composition is composed of the following raw materials in parts by weight: the DHA-containing algal oil 40-42 parts, the extract
of Bacopa monnieri 13-15 parts, tyrosine 1-2 parts, L-lysine monohydrochloride 1-2
parts, glutamine 1-2 parts, the choline bitartrate powder 1.5-2.5 parts, the flaxseed oil 0.5-1 parts, the phospholipids 1-1.5 parts, glyceryl monostearate/distearate 1-1.5 parts,
and D-alpha-tocopherol 0.2-0.4 parts.
[0008] Preferably, the brain-invigorating composition is composed of the following raw materials in parts by weight: the DHA-containing algal oil 41 parts, the extract of
Bacopa monnieri 14 parts, tyrosine 1.5 parts, L-lysine monohydrochloride 1.5 parts,
glutamine 1.5 parts, the choline bitartrate powder 2 parts, the flaxseed oil 0.7 parts, the phospholipids 1.3 parts, glyceryl monostearate/distearate 1.3 parts, and
D-alpha-tocopherol 0.3 parts.
[0009] Based on the same technical concept, another technical solution of the present disclosure is providing the method for preparing the brain-invigorating composition,
comprising the following steps:
[0010] (1) heating and mixing the flaxseed oil, the phospholipids and glyceryl monostearate/distearate, to obtain a mixture A;
[0011] (2) adding the DHA-containing algal oil and the extract of Bacopa monnieri to the mixture A to mix, and then filtering to obtain a mixture B; and
[0012] (3) mixing the mixture B with tyrosine, L-lysine monohydrochloride, glutamine, the choline bitartrate powder, and D-alpha-tocopherol, and stirring evenly to obtain the brain-invigorating composition.
[0013] Preferably, in the step (1), the heating is carried out at 40-50 °C, and the mixing is carried out with a rotating speed of 60-80 r/min.
[0014] Preferably, in the step (2), the mixing is carried out for 20-30 min with the rotating speed of 50-70 r/min; and the filtering is carried out by passing through an
-100 mesh sieve.
[0015] Preferably, in the step (3), the stirring is carried out for 30-40 min with the rotating speed of 40-60 r/min.
[0016] To facilitate the understanding of the present disclosure, the functions of some of the raw materials are described.
[0017] The DHA-containing algal oil: DHA, commonly known as brain gold, is a major element for the growth and development of cells in the nervous system, and an important fatty acid constituting the brain and retina, with its content in the human
cerebral cortex up to 20% and in the retina up to 50%. DHA is essential for infant intellectual and visual development. The DHA-containing algal oil is extracted from
marine microalgae, which is relatively safer due to not being transmitted along the food chain, and its EPA content is very low.
[0018] Bacopa monnieri: (1) Bacopa monnieri has a strong antioxidant effect, capable of slowing down the aging of brain cells; (2) Bacopa monnieri has the effect of promoting brain functions, such as improving memory, attention and the ability to
process visual information; (3) Bacopa monnieri has the effect of reducing stress and
anxiety by boosting mood and lowering cortisol levels.
[0019] Glutamine: Glutamine has the effect of promoting the brain development and enhancing memory for children, maintaining the brain activity and preventing dementia
for the elderly, and preventing the brain fatigue for workers.
[0020] The beneficial effects of the present disclosure are as follows:
[0021] Demonstrated by the relevant tests, the brain-invigorating composition, with scientific and reasonable proportions, is capable of significantly improving attention,
concentration, memory, learning ability, and language comprehension. There is no
obvious change in the important blood indicators of the human body after taking the brain-invigorating composition. Even if there is a change, it is within a reasonable range.
Thus, taking the brain-invigorating composition would not cause a negative impact on
the human body.
[0022] To make the objectives, technical solutions and advantages of the present disclosure clearer, the technical solutions of the present disclosure will be described in detail below. Obviously, the described examples are only part but not all of examples of the present disclosure. Based on the examples of the present disclosure, all other implementations obtained by those ordinarily skilled in the art without creative work shall fall within the protection scope of the present disclosure.
[0023] Example 1
[0024] The method for preparing the brain-invigorating composition is provided by this example, including the following steps:
[0025] (1) 5 g of the flaxseed oil, 10 g of the phospholipids, and 10 g of glyceryl monostearate/distearate are heated at 40 °C, and stirred with the rotating speed of 60
r/min to mix evenly, to obtain the mixture A.
[0026] (2) 400 g of the DHA-containing algal oil and 130 g of the extract of Bacopa monnieri are added into the mixture A to mix for 20 min with the rotating speed of 50 r/min, and then filtered through the 80-mesh sieve, to obtain the mixture B.
[0027] (3) The mixture B is mixed with 10 g of tyrosine, 10 g of L-lysine monohydrochloride, 10 g of glutamine, 15 g of the choline bitartrate powder, and 2 g of D-alpha-tocopherol to stir for 30 min with the rotating speed of 40 r/min, to obtain the
brain-invigorating composition.
[0028] Example 2
[0029] The method for preparing the brain-invigorating composition is provided by this example, including the following steps:
[0030] (1) 10 g of the flaxseed oil, 15 g of the phospholipids, and 15 g of glyceryl monostearate/distearate are heated at 50 °C, and stirred with the rotating speed of 80
r/min to mix evenly, to obtain the mixture A.
[0031] (2) 420 g of the DHA-containing algal oil and 150 g of the extract of Bacopa monnieri are added into the mixture A to mix for 30 min with the rotating speed of 70
r/min, and then filtered through the 100-mesh sieve, to obtain the mixture B.
[0032] (3) The mixture B is mixed with 20 g of tyrosine, 20 g of L-lysine monohydrochloride, 20 g of glutamine, 25 g of the choline bitartrate powder, and 4 g of
D-alpha-tocopherol to stir for 40 min with the rotating speed of 60 r/min, to obtain the brain-invigorating composition.
[0033] Example 3
[0034] The method for preparing the brain-invigorating composition is provided by this example, including the following steps:
[0035] (1) 5 g of the flaxseed oil, 15 g of the phospholipids, and 10 g of glyceryl monostearate/distearate are heated at 45 °C, and stirred with the rotating speed of 70
r/min to mix evenly, to obtain the mixture A.
[0036] (2) 400 g of the DHA-containing algal oil and 150 g of the extract of Bacopa monnieri are added into the mixture A to mix for 25 min with the rotating speed of 60
r/min, and then filtered through the 90-mesh sieve, to obtain the mixture B.
[0037] (3) The mixture B is mixed with 10 g of tyrosine, 20 g of L-lysine monohydrochloride, 10 g of glutamine, 25 g of the choline bitartrate powder, and 2 g of
D-alpha-tocopherol to stir for 35 min with the rotating speed of 50 r/min, to obtain the brain-invigorating composition.
[0038] Example 4
[0039] The method for preparing the brain-invigorating composition is provided by this example, including the following steps:
[0040] (1) 10 g of the flaxseed oil, 10 g of the phospholipids, and 15 g of glyceryl monostearate/distearate are heated at 45 °C, and stirred with the rotating speed of 70 r/min to mix evenly, to obtain the mixture A.
[0041] (2) 420 g of the DHA-containing algal oil and 130 g of the extract of Bacopa monnieri are added into the mixture A to mix for 25 min with the rotating speed of 60
r/min, and then filtered through the 90-mesh sieve, to obtain the mixture B.
[0042] (3) The mixture B is mixed with 20 g of tyrosine, 10 g of L-lysine monohydrochloride, 20 g of glutamine, 15 g of the choline bitartrate powder, and 4 g of
D-alpha-tocopherol to stir for 35 min with the rotating speed of 50 r/min, to obtain the
brain-invigorating composition.
[0043] Example 5
[0044] The method for preparing the brain-invigorating composition is provided by this example, including the following steps:
[0045] (1) 7 g of the flaxseed oil, 13 g of the phospholipids, and 13 g of glyceryl monostearate/distearate are heated at 45 °C, and stirred with the rotating speed of 70 r/min to mix evenly, to obtain the mixture A.
[0046] (2) 410 g of the DHA-containing algal oil and 140 g of the extract of Bacopa monnieri are added into the mixture A to mix for 25 min with the rotating speed of 60
r/min, and then filtered through the 90-mesh sieve, to obtain the mixture B.
[0047] (3) The mixture B is mixed with 15 g of tyrosine, 15 g of L-lysine monohydrochloride, 15 g of glutamine, 20 g of the choline bitartrate powder, and 3 g of D-alpha-tocopherol to stir for 35 min with the rotating speed of 50 r/min, to obtain the
brain-invigorating composition.
[0048] Test example
[0049] To demonstrate the efficacy of the brain-invigorating composition of the present disclosure, the following tests are conducted.
[0050] (I) The criteria for selecting subjects are as follows:
[0051] (1) There are totally 60 subjects with the age of 19-22 years old enrolled, including male and female;
[0052] (2) The subjects shall have basic computer knowledge and experience for computer tests;
[0053] (3) The subjects shall participate in the tests voluntarily and sign the informed consent.
[0054] (II) Subjects shall be excluded if they meet any of the following situations:
[0055] (1) The person who has recently taken any drugs to improve memory;
[0056] (2) The person who frequently drinks, smokes or takes any drugs that affect the central nervous system;
[0057] (3) The person who suffers from any allergic disease;
[0058] (4) The person who suffers from chronic diseases such as hypertension, ischemic heart disease, diabetes, respiratory system diseases, cardiovascular system diseases, mental illness or other central nervous system diseases;
[0059] (5) The person who participated in any drug trials or donated blood in the past month.
[0060] (III) Test method and process
[0061] The participants take the tablet of the brain-invigorating composition prepared in Example 5 with the dosage of 150 mg or the placebo in a random arrangement, and
both medicines have the same weight, color, shape, size and package. The participants take the medication orally twice a day for 15 days. The participants are required to take
the medication on a regular basis, and any omissions are recorded. The participants are recalled after taking the medication for 15 days to do related examinations and
supplement the medicines, with all unused medicines required to be returned. And then the participants are provided with the medicines for the next 15 days. The duration of
medication is 45 days in total, and the participants are tested after stopping the medication 15 days.
[0062] (IV) Blood test
[0063] The blood sampling of the participants are conducted for testing, and all 60 participants undergo the same procedure on the day of test: 5 mL of venous blood is
taken from the forearm and stored in sterile and deionized glass test tube. The following
indicators are detected via the blood test: serum calcium, serum triglyceride, serum cholesterol, serum high-density lipoprotein and serum low-density lipoprotein.
[0064] The results are shown in Table 2.
[0065] (V) Specific test content
[0066] A series of auditory and visual neuropsychological tests are selected to assess immediate recall, recognition, working memory, attention, associative ability, reasoning, translation and language comprehension, which include digital span test, paired-associate test, logical memory test, nonsense syllables memory test, finger
tapping test, simple reaction time test, choice reaction time test, choice discrimination test and digital symbol test. The results of those tests are given in score. Higher score
means better performance. The details are as follows:
[0067] (1) Digital span test: The participants are asked to verbally recall a sequence of numbers ranging from 6 to 10 in two manners: recalling the numbers from left to right
(forward) and from right to left (backward).
[0068] (2) Paired-associate test: There are total ten word-pairs presenting to the participants before testing. Then, the participants are presented with one prompt word of the ten word-pairs, and required to verbally answer the target word paired with the prompt word. The participants are required to have the ability to associate words, that is, the reasoning and translation ability.
[0069] (3) Logical memory test: The logical memory test is about the recalling of a story. The parallel test is conducted to the participants before and after taking the
medication. The test requires the participants to have good language comprehension, and immediately recall a logical event. The parallel test conducted before and after
taking the medication has high comparability.
[0070] (4) Nonsense syllables memory test: This test is to measure the memory of the participants for nonsense syllables, which helps to better measure the subtle difference of the memory ability. Sometimes, the participants could recognize related syllables
even though they couldn't recall the relevant details contained in the preceding description.
[0071] (5) Finger tapping test: This test is to assess the movement behavior with the duration of 8 s, and the participants must keep tapping the buttons on the keyboard rapidly and consecutively to response the test. The results of the test are based on time
and success rate.
[0072] (6) Simple reaction time test: This test is to evaluate the attention and response of the brain. When the button is pressed to start the test, a photo of a boy would appear
randomly in the center of the screen 20 times. Then, when the photo of the boy appears, the participants have to respond by pressing the "BOY" symbol button on the keyboard.
In the test, the photo stays on the screen for 1 s, and the time interval for the photo
appearing subsequently is 1.5-2.5 s. The results are based on time.
[0073] (7) Choice reaction time test: This test is to assess the attention and response of the brain, and estimate the psychomotor speed. When the participants press the button to
start the test, and a photo of a boy or a girl randomly appears in the center of the monitor screen 20 times. Then, when the photo of the boy appears, the participants have
to respond by pressing the "BOY" symbol button on the keyboard as soon as possible.
Each photo stays on the screen for 1 s, and the time interval for the photo appearing subsequently is 1.5-2.5 s. The results are calculated based on average reaction time, correct rate and the number of errors.
[0074] (8) Choice discrimination test: This test is to assess the attention and response of the brain, and estimate the psychomotor speed. When the participants press the
button to start the test, and a photo of a boy or a girl randomly appears in the center of the monitor screen. The photo of the boy and the photo of the girl would each appear 10 times randomly during the test. Then, when the photo appears, the participants have to
press the corresponding "BOY" symbol button or "GIRL" symbol button on the
keyboard correctly. Each photo stays on the screen for 1 s, and the time interval for the photo appearing subsequently is 1.5-2.5 s.
[0075] (9) Digital symbol test: Each target are required to be replaced with the digital picture. In this test, the upper panel of the screen displays the target picture
corresponding to a row of numbers 1 through 9. The participants have to memorize each number and its corresponding picture carefully. When the button is pressed to start, the
pictures would appear randomly on the screen, and the participants have to input the
corresponding numbers on the keyboard as quickly as possible by pressing the corresponding picture, thereby replacing pictures as many as possible within 90 s.
Reaction time, total attempts, correct attempts and wrong attempts are calculated in this
test. Manual speed and agility have a significant impact on the results.
[0076] The test results are shown in Table 3.
[0077] (VI) Test results and conclusions
[0078] Table 2 The results of the blood test Test items Test group (36 persons) Placebo group (24 persons) P value Before taking After taking Before taking After taking the the the the medication medication medication medication Serum 9.9 0.5 10.2 0.6 10.2 0.8 9.9 0.5 < 0.05 calcium (mg/dL) Serum 128.6 40.3 130.4 42.3 144.6 39.4 134.6 37 > 0.05 triglyceride (mg%) Serum 142.8 24.8 135.8 23.6 146.7 26.2 134.7 17.9 > 0.05 cholesterol (mg%) Serum 39.6 8.4 45.1 10.4 40.5 9.4 41 8.7 > 0.05 high-density lipoprotein (mg%) Serum 71.2 19.0 71.7±18.6 77.3 16.5 66.2 12.0 > 0.05 low-density lipoprotein (mg%)
[0079] Table 3 The results of the auditory and visual neuropsychological tests Test items Test group (36 persons) Placebo group (24 persons) P Before taking After taking Before taking After taking value the medication the medication the the medication medication Digital span test 7.23 1.11 7.85 0.83 7.83 1.19 7.73 0.23 > 0.05 (forward) Digital span test 8.1 ±1.3 8.3± 0.9 9.1m1.0 8.3± 0.8 < 0.05 (backward) Paired-associate 8± 1.3 7.7± 1.4 8.1m1.1 7.9± 1.3 > 0.05 test Logical 3.4 2.6 5.2 4.5 5.5 2.6 4.1 3.8 < 0.05 memory test Nonsense 5.4 3.3 6.9 2.4 4.7 2.3 6.1 2.9 > 0.05 syllables memory test Finger tapping 152.28 15.75 154.56 13.71 157.60 158.48 27.89 > 0.05 test 14.89 Simple reaction 221.88 53.17 221.01 52.16 213.13 33.6 212.49 33.62 > 0.05 time test Choice reaction 350.07 52.08 340.03 62.26 342.39 340.95 64.45 > 0.05 time test 67.54 Choice 383.70 52.54 387.06 53.47 374.02 379.44 58.32 > 0.05 discrimination 51.46 test Digital symbol 1492.69 1467.78 1465.94 1325.44 > 0.05 test 368.58 556.55 293.94 207.07
[0080] As can be seen from Table 2, in the test group after taking the medication, the increase level of serum calcium is within the normal range, and the content of serum cholesterol is significantly reduced, but both are not statistically significant compared
with the results of the placebo group. And the serum high-density lipoprotein level is
significantly increased, but no statistical difference compared with the placebo group.
There is no statistically significant difference among the other blood parameters studied in Table 2. The blood test mainly evaluates the efficacy of the brain-invigorating
composition on memory. The results show an increase in the serum calcium level in the
test group, which is significant compared with the results of the placebo group. The increased serum calcium level remains within the normal range (9-11 mg/dL).
[0081] As can be seen from Table 3, the digital span test (backward) and the logical memory test show statistically significant improvements in the test group compared
with the placebo group. From the neuropsychological perspective, the test group taking the brain-invigorating composition has significant improvements in attention, concentration and memory, which can be demonstrated through the digital span test (backward) (p < 0.05). At the same time, there are also significant improvements (p <
0.05) in the results of the logical memory test which requires the participants to learn
new materials and recall in a short time, and is mainly used to assess memory, recall, language comprehension and learning ability. Compared with the placebo group, the test
group shows significant improvements in memory in the digital span test (backward),
but no statistically significant difference, indicating that the brain-invigorating composition is capable of improving attention to a certain extent.
[0082] The above-mentioned examples are only specific examples of the present disclosure, not intended to limit the protection scope of the present disclosure. Changes or replacements made by those skilled in the art within the technical scope disclosed by
the present disclosure shall fall within the protection scope of the present disclosure. Therefore, the protection scope of the present disclosure shall be subject to the
protection scope of the claims.
Claims (7)
1. A brain-invigorating composition, wherein, the brain-invigorating composition is
composed of the following raw materials: a DHA-containing algal oil, an extract of
Bacopa monnieri, tyrosine, L-lysine monohydrochloride, glutamine, a choline bitartrate
powder, flaxseed oil, phospholipids, glyceryl monostearate/distearate, and
D-alpha-tocopherol.
2. The brain-invigorating composition according to claim 1, wherein, the
brain-invigorating composition is composed of the following raw materials in parts by
weight: the DHA-containing algal oil 40-42 parts, the extract of Bacopa monnieri 13-15
parts, tyrosine 1-2 parts, L-lysine monohydrochloride 1-2 parts, glutamine 1-2 parts, the
choline bitartrate powder 1.5-2.5 parts, the flaxseed oil 0.5-1 parts, the phospholipids
1-1.5 parts, glyceryl monostearate/distearate 1-1.5 parts, and D-alpha-tocopherol 0.2-0.4
parts.
3. The brain-invigorating composition according to claim 2, wherein, the
brain-invigorating composition is composed of the following raw materials in parts by
weight: the DHA-containing algal oil 41 parts, the extract of Bacopa monnieri 14 parts,
tyrosine 1.5 parts, L-lysine monohydrochloride 1.5 parts, glutamine 1.5 parts, the
choline bitartrate powder 2 parts, the flaxseed oil 0.7 parts, the phospholipids 1.3 parts,
glyceryl monostearate/distearate 1.3 parts, and D-alpha-tocopherol 0.3 parts.
4. A method for preparing the brain-invigorating composition of any one of claims
1-3, wherein, comprising the following steps:
(1) heating and mixing the flaxseed oil, the phospholipids and glyceryl
monostearate/distearate, to obtain a mixture A;
(2) adding the DHA-containing algal oil and the extract of Bacopa monnieri to the
mixture A to mix, and then filtering to obtain a mixture B; and
(3) mixing the mixture B with tyrosine, L-lysine monohydrochloride, glutamine,
the choline bitartrate powder, and D-alpha-tocopherol, and stirring evenly to obtain the
brain-invigorating composition.
5. The method for preparing the brain-invigorating composition according to claim 4, wherein, in the step (1), the heating is carried out at 40-50 °C, and the mixing is carried out with a rotating speed of 60-80 r/min.
6. The method for preparing the brain-invigorating composition according to claim
4, wherein, in the step (2), the mixing is carried out for 20-30 min with the rotating
speed of 50-70 r/min; and the filtering is carried out by passing through an 80-100 mesh sieve.
7. The method for preparing the brain-invigorating composition according to claim
4, wherein, in the step (3), the stirring is carried out for 30-40 min with the rotating
speed of 40-60 r/min.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210030268.4A CN114287626A (en) | 2022-01-12 | 2022-01-12 | Brain-strengthening composition and preparation method thereof |
| CN202210030268.4 | 2022-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022201543A1 true AU2022201543A1 (en) | 2023-07-27 |
Family
ID=80976683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022201543A Pending AU2022201543A1 (en) | 2022-01-12 | 2022-03-04 | Brain-invigorating composition and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114287626A (en) |
| AU (1) | AU2022201543A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ530554A (en) * | 2004-01-13 | 2004-04-30 | A | Neuronutrients |
| WO2014025905A1 (en) * | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| WO2014047614A1 (en) * | 2012-09-24 | 2014-03-27 | Abbott Laboratories | Nutritional compositions and methods for enhancing cognitive function and muscle function |
| WO2017006351A1 (en) * | 2015-07-09 | 2017-01-12 | Chitra Vasant Savangikar | Herbal dha composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833692B (en) * | 2005-03-15 | 2010-08-11 | 成都华高药业有限公司 | False portulaca oleracea extracts, its prepn. and usage |
| CN105287430A (en) * | 2015-12-01 | 2016-02-03 | 广州市富诺生物科技有限公司 | Algae oil soft capsule and preparation method thereof |
| CN106267106A (en) * | 2016-09-26 | 2017-01-04 | 宋妮 | Promote the compositions of memory improvement patients of senile dementia brain health status |
| CN112656864A (en) * | 2020-12-24 | 2021-04-16 | 深圳市旷逸生物科技有限公司 | Pharmaceutical composition containing NMN and Bacopa monnieri extract |
-
2022
- 2022-01-12 CN CN202210030268.4A patent/CN114287626A/en active Pending
- 2022-03-04 AU AU2022201543A patent/AU2022201543A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ530554A (en) * | 2004-01-13 | 2004-04-30 | A | Neuronutrients |
| WO2014025905A1 (en) * | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| WO2014047614A1 (en) * | 2012-09-24 | 2014-03-27 | Abbott Laboratories | Nutritional compositions and methods for enhancing cognitive function and muscle function |
| WO2017006351A1 (en) * | 2015-07-09 | 2017-01-12 | Chitra Vasant Savangikar | Herbal dha composition |
Non-Patent Citations (1)
| Title |
|---|
| Therapeutic Goods Administration (TGA); "Visdon Brainbook Concentration Support (ARTG ID 371690)", 27 July 2021. www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=371690&agid=%28PrintDetailsPublic%29&actionid=1. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114287626A (en) | 2022-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Siebelink et al. | Psychological effects of subclinical epileptiform EEG discharges in children. II. General intelligence tests | |
| Braud et al. | The use of electromyographic biofeedback in the control of hyperactivity | |
| Platt et al. | Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children | |
| US8962042B2 (en) | Methods for treating neurological disorders using nutrient compositions | |
| US11369652B2 (en) | Methods for treating neurological disorders using nutrient compositions | |
| Crook et al. | The effect of methylphenidate on test performance in the cognitively impaired aged | |
| Saab et al. | Influence of ethnicity and gender on cardiovascular responses to active coping and inhibitory-passive coping challenges | |
| Reich et al. | Effect of a hypoglycemic episode on neuropsychological functioning in diabetic children | |
| Petlovanyi et al. | Practical guide and some recommendations for the diagnosis and management of Attention deficit hyperactivity disorder (ADHD) | |
| AU2022201543A1 (en) | Brain-invigorating composition and preparation method thereof | |
| Poon et al. | Active living, cognitive functioning, and aging | |
| Darley et al. | The effect of alerting and tranquilizing drugs upon the performance of aphasic patients | |
| Landauer et al. | The effect of medazepam and alcohol on cognitive and motor skills used in car driving | |
| US20150306164A1 (en) | Uses of bacopa monnieri extract | |
| Talland et al. | Performance tests of amnesic patients with Cylert | |
| Delaney et al. | An exploration of the verbal encodability hypothesis for sex differences in the digit-symbol (symbol-digit) test | |
| Wohlgemuth | On the feelings and their neural correlate, with an examination of the nature of pain | |
| Byrne | Cognitive‐perceptual abilities of a neurologically impaired infant: an alternative assessment strategy | |
| Zhu et al. | The Physical and Mental Rehabilitation Effect of Healthy-mind Exercise intervention on Individuals of Illicit Drug Dependent: 3258 Board# 1 June 1 9: 00 AM-11: 00 AM | |
| Tena | The body as a tattletale: Physiological responses to food stimuli perception within the context of expectations | |
| Eyes et al. | A Survivor’s Guide to Beating Cancer | |
| Khattab | The Effects of Exercise on Cognition Post-Stroke: Are There Sex Differences? | |
| Popova | AGE FEATURES OF THE INFLUENCE OF COLOR ON THE PSYCHOPHYSIOLOGICAL FUNCTIONS OF THE ORGANISM | |
| AU2015254865A1 (en) | Administration of citicoline to improve cognitive performance, attentional performance, and motor function | |
| Ratlidge | Mitigation of the impact of cognitive fatigue on simple motor performance by phytochemicals: the effect of a blackcurrant supplement: a thesis presented in partial fulfilment of the requirements for the degree of Master of Arts in Psychology at Massey University, Manawatū, New Zealand |